Details

Autor(en) / Beteiligte

• Rawstron, Andy C.
• Gregory, Walter M.
• de Tute, Ruth M.
• Davies, Faith E.
• Bell, Sue E.
• Drayson, Mark T.
• Cook, Gordon
• Jackson, Graham H.
• Morgan, Gareth J.
• Child, J. Anthony
• Owen, Roger G.

Titel

Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction

Ist Teil von

• Blood, 2015-03, Vol.125 (12), p.1932-1935

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2015

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• The detection of minimal residual disease (MRD) in myeloma using a 0.01% threshold (10−4) after treatment is an independent predictor of progression-free survival (PFS), but not always of overall survival (OS). However, MRD level is a continuous variable, and the predictive value of the depth of tumor depletion was evaluated in 397 patients treated intensively in the Medical Research Council Myeloma IX study. There was a significant improvement in OS for each log depletion in MRD level (median OS was 1 year for ≥10%, 4 years for 1% to <10%, 5.9 years for 0.1% to <1%, 6.8 years for 0.01% to <0.1%, and more than 7.5 years for <0.01% MRD). MRD level as a continuous variable determined by flow cytometry independently predicts both PFS and OS, with approximately 1 year median OS benefit per log depletion. The trial was registered at www.isrctn.com as #68454111. •The level of MRD quantified by flow cytometry is more informative than a 0.01% threshold and independently predicts OS.•There was approximately 1 year survival benefit per log depletion. A lower cut point for predicting improved outcome was not reached.